A vaccine first developed to protect koalas from a devastating disease is now offering rare insights that could help accelerate human vaccine development for one of the world's most common sexually transmitted infections.
University of the Sunshine Coast researchers say koalas are the first wildlife species to receive conditional approval for a vaccine against chlamydia, a bacterial infection that causes blindness, infertility and premature death in the iconic marsupial.
In a new paper published in Trends in Microbiology , UniSC scientists outline how more than a decade of koala vaccination research is providing lessons for global efforts to develop a human chlamydia vaccine, something that has so far eluded scientists.
Lead author Dr Nina Pollak, from UniSC's Centre for Bioinnovation , said the koala program had progressed faster than human vaccine efforts because researchers could observe disease outcomes directly in the natural host.
"Koalas develop visible eye and urogenital disease, which means we can see whether vaccination is actually reducing illness and death over time," Dr Pollak said.
"That kind of real‑world evidence is extremely difficult to obtain in humans, where most chlamydia infections are silent but can still cause serious long‑term damage."
Unlike laboratory models or short clinical trials, koalas are naturally exposed to infection throughout their lives. This has allowed researchers to track vaccine safety, immune responses and health outcomes under real environmental conditions.
Field studies involving hundreds of wild koalas showed vaccinated animals experienced lower rates of chlamydial disease and reduced mortality, without signs the vaccine was causing the bacteria to evolve or 'escape' immune pressure.
The single‑dose vaccine targets the most common strains of chlamydia affecting Australian koalas and includes three immune-boosting ingredients that work together to train the immune system to recognise and attack the infection, an approach researchers are also exploring for human vaccines.
Dr Pollak said the work challenged the idea that vaccine development must always follow a "human‑first" pathway.
"Our research shows that carefully designed wildlife vaccination programs can generate high‑quality evidence that complements human trials, particularly for complex pathogens where traditional approaches are slow or constrained," she said.
The koala vaccine has been authorised for supervised use under Australia's veterinary minor‑use pathway , reflecting the ethical and practical challenges of running conventional trials in an endangered species.
While the vaccine is not a commercial product, researchers say it is already delivering conservation benefits and helping shape thinking about how vaccines might be evaluated when controlled challenge studies are not possible.
"Koalas are helping us rethink how we gather evidence, how we assess success, and how we move promising vaccines forward when the usual rulebook doesn't apply," Dr Pollak said.
